RxDoctor Payments Data

Lannis Hall, MD

Radiation Oncology · Saint Peters, MONPI 1558472514

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,860 of the $14,171 with a category attached, or 69.6%. 13 manufacturers reported payments, led by Bioprotect Medical, Inc. at 37.7% of the total. 2025 is the largest year on record at $5,866, more than ten times the $554 reported in 2019. Among radiation oncology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,171in general payments, 2019–2025

Across 30 payments — averaging $472.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bioprotect Medical, Inc.$5K
  • Astellas Pharma US Inc$4K
  • AstraZeneca$3K
  • Boston Scientific$522
  • Theragenics Corporation$484
  • Ferring Pharmaceuticals Inc.$125
  • plus $316 from 7 others

What the payments were for

  • Consulting fees$9,86070%
  • Travel & lodging$1,2599%
  • Food & beverage$3,05222%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,171 in reported general payments places this provider in the 90th percentile of 123 radiation oncology providers in Missouri.

See all radiation oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$288,763
Medicare patients
361
Services billed
2,827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix27$82,794
Tamsulosin Hcl269$3,632
Sucralfate11$2,386
Pilocarpine Hcl12$1,428
Bicalutamide51$1,135
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$799
Oxybutynin Chloride ErOxybutynin Chloride35$679
Levothyroxine Sodium96$568
Venlafaxine Hcl ErVenlafaxine Hcl27$463
Lidocaine Hcl ViscousLidocaine Hcl19$460
Oxybutynin Chloride12$245
Ciprofloxacin Hcl62$243
Pregabalin14$223
Mometasone Furoate11$195
Silver Sulfadiazine16$195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx$67$82,79427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 123 radiation oncology providers in Missouri.

Other radiation oncology in Saint Peters

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →